WORLD JOURNAL OF PHARMACY
AND MEDICAL SCIENCE

An International Peer-Reviewed Open Access Journal
Fast, Transparent Publication for Researchers in Pharmaceutical and Medical Sciences

ISSN:3049-3501




Submit Article



ABSTRACT

AN ANALYSIS OF THE DRUG UTILIZATION PATTERNS OBSERVED IN PATIENTS WITH HYPERLIPIDEMIA

Vidhun M.*, Dr. R. Dinesh Kumar*, Dr. M. Alagarraja*, Dr. D. Christopher Vimalson*, Ashitha K. S.*

Background: Hyperlipidemia is a major risk factor for atherosclerosis and cardiovascular diseases. Evaluating drug utilization patterns provides critical insights into clinical practice and rational medicine use. Aim: To analyze the drug utilization patterns, clinical characteristics, and treatment outcomes among patients with hyperlipidemia in a hospital setting. Methodology: A retrospective observational study was conducted involving 150 hyperlipidemic patients receiving lipid-lowering pharmacotherapy at Visva Medical Centre and Hospital. Demographic data, prescribed treatment regimens, baseline, and post-treatment lipid profiles (Total Cholesterol, LDL, HDL, and Triglycerides) were collected and analyzed. Statistical significance was assessed using p-values. Results: Among the 150 participants, males constituted 53.33% (n=80) and females 46.67% (n=70). The majority of patients belonged to the 41–50 age group (n=42) and were classified as overweight based on BMI (n=65). Statin monotherapy was the predominant treatment choice. Atorvastatin was the most frequently prescribed agent (38.00%, n=57), followed by Rosuvastatin (26.67%, n=40), and Fenofibrate (20.00%, n=30). Combination therapy was prescribed in 15.34% (n=23) of patients. Post-treatment evaluation demonstrated statistically significant improvements across all lipid parameters (p < 0.001). Rosuvastatin monotherapy achieved the lowest current mean LDL level (114.35 mg/dL), Atorvastatin showed the highest mean HDL level (50.70 mg/dL), and Fenofibrate + Atorvastatin combination achieved the lowest triglyceride levels (161.60 mg/dL). Conclusion: Atorvastatin was the most commonly utilized lipid-lowering drug. All prescribed monotherapies and combination regimens resulted in statistically significant improvements in lipid profiles, demonstrating effective therapeutic outcomes in routine clinical practice.

[Full Text Article]

NEWS

  • Email & SMS Alert

    We will provide you email alerts regarding New Issue Release, Publication of your Article, Invitaion for New Upcoming Issue, Manuscript releted Emails etc.

    August 2026 Issue Released

    We are delighted to announce the release of the August 2026 Issue. The issue is now live and accessible on the journal website for readers and contributors. You can check now: Click here

    Indexing

    This journal is indexed in world wide reputed commettee like: "DOI for all Articles" "Google Scholar" "ISI Scientific indexing" "ACADEMIA" "Chemical Abstracts Service (CAS)" "Cosmos Indexing" "ResearchBib" "IP Indexing" "Zenodo Indexing" etc.